6d48

From Proteopedia

(Difference between revisions)

Current revision

Cell Surface Receptor

Structural highlights

6d48 is a 4 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:	X-ray diffraction, Resolution 1.776Å
Resources:	FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

CD33_HUMAN Putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Induces apoptosis in acute myeloid leukemia (in vitro).^[1] ^[2]

Publication Abstract from PubMed

Polymorphism in the microglial receptor CD33 gene has been linked to late-onset Alzheimer disease (AD), and reduced expression of the CD33 sialic acid-binding domain confers protection. Thus, CD33 inhibition might be an effective therapy against disease progression. Progress toward discovery of selective CD33 inhibitors has been hampered by the absence of an atomic resolution structure. We report here the crystal structures of CD33 alone and bound to a subtype-selective sialic acid mimetic called P22 and use them to identify key binding residues by site-directed mutagenesis and binding assays to reveal the molecular basis for its selectivity toward sialylated glycoproteins and glycolipids. We show that P22, when presented on microparticles, increases uptake of the toxic AD peptide, amyloid-beta (Abeta), into microglial cells. Thus, the sialic acid-binding site on CD33 is a promising pharmacophore for developing therapeutics that promote clearance of the Abeta peptide that is thought to cause AD.

Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes Abeta Phagocytosis.,Miles LA, Hermans SJ, Crespi GAN, Gooi JH, Doughty L, Nero TL, Markulic J, Ebneth A, Wroblowski B, Oehlrich D, Trabanco AA, Rives ML, Royaux I, Hancock NC, Parker MW iScience. 2019 Sep 27;19:110-118. doi: 10.1016/j.isci.2019.07.023. Epub 2019 Jul , 19. PMID:31369984^[3]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

↑ Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol. 1999 Nov;29(11):3440-9. PMID:10556798 doi:http://dx.doi.org/10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.0.CO;2-C
↑ Vitale C, Romagnani C, Puccetti A, Olive D, Costello R, Chiossone L, Pitto A, Bacigalupo A, Moretta L, Mingari MC. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5764-9. Epub 2001 Apr 24. PMID:11320212 doi:http://dx.doi.org/10.1073/pnas.091097198
↑ Miles LA, Hermans SJ, Crespi GAN, Gooi JH, Doughty L, Nero TL, Markulic J, Ebneth A, Wroblowski B, Oehlrich D, Trabanco AA, Rives ML, Royaux I, Hancock NC, Parker MW. Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes Abeta Phagocytosis. iScience. 2019 Sep 27;19:110-118. doi: 10.1016/j.isci.2019.07.023. Epub 2019 Jul , 19. PMID:31369984 doi:http://dx.doi.org/10.1016/j.isci.2019.07.023

1 Structural highlights
2 Function
3 Publication Abstract from PubMed
4 References

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/6d48"

Categories: Homo sapiens | Large Structures | Hermans SJ | Miles LA | Parker MW

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
-The entry 6d48 is ON HOLD  until Paper Publication
+==Cell Surface Receptor==
+<StructureSection load='6d48' size='340' side='right'caption='[[6d48]], [[Resolution|resolution]] 1.78&Aring;' scene=''>
+== Structural highlights ==
+<table><tr><td colspan='2'>[[6d48]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6D48 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6D48 FirstGlance]. <br>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.776&#8491;</td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6d48 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6d48 OCA], [https://pdbe.org/6d48 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6d48 RCSB], [https://www.ebi.ac.uk/pdbsum/6d48 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6d48 ProSAT]</span></td></tr>
+</table>
+== Function ==
+[https://www.uniprot.org/uniprot/CD33_HUMAN CD33_HUMAN] Putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Induces apoptosis in acute myeloid leukemia (in vitro).<ref>PMID:10556798</ref> <ref>PMID:11320212</ref>
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+Polymorphism in the microglial receptor CD33 gene has been linked to late-onset Alzheimer disease (AD), and reduced expression of the CD33 sialic acid-binding domain confers protection. Thus, CD33 inhibition might be an effective therapy against disease progression. Progress toward discovery of selective CD33 inhibitors has been hampered by the absence of an atomic resolution structure. We report here the crystal structures of CD33 alone and bound to a subtype-selective sialic acid mimetic called P22 and use them to identify key binding residues by site-directed mutagenesis and binding assays to reveal the molecular basis for its selectivity toward sialylated glycoproteins and glycolipids. We show that P22, when presented on microparticles, increases uptake of the toxic AD peptide, amyloid-beta (Abeta), into microglial cells. Thus, the sialic acid-binding site on CD33 is a promising pharmacophore for developing therapeutics that promote clearance of the Abeta peptide that is thought to cause AD.
-Authors:
+Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes Abeta Phagocytosis.,Miles LA, Hermans SJ, Crespi GAN, Gooi JH, Doughty L, Nero TL, Markulic J, Ebneth A, Wroblowski B, Oehlrich D, Trabanco AA, Rives ML, Royaux I, Hancock NC, Parker MW iScience. 2019 Sep 27;19:110-118. doi: 10.1016/j.isci.2019.07.023. Epub 2019 Jul , 19. PMID:31369984<ref>PMID:31369984</ref>
-Description:
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-[[Category: Unreleased Structures]]
+</div>
+<div class="pdbe-citations 6d48" style="background-color:#fffaf0;"></div>
+== References ==
+<references/>
+__TOC__
+</StructureSection>
+[[Category: Homo sapiens]]
+[[Category: Large Structures]]
+[[Category: Hermans SJ]]
+[[Category: Miles LA]]
+[[Category: Parker MW]]

6d48

From Proteopedia

Current revision

Cell Surface Receptor

Structural highlights

Function

Publication Abstract from PubMed

References

Contents

Proteopedia Page Contributors and Editors (what is this?)

Views

Personal tools

Navigation

Search

Toolbox